TIGP (BIO)—Exploration for Personalized Combinatorial Chemotherapies for Cancers
- 講者李心予 教授 (國立台灣大學電機工程學系)
邀請人：TIGP (Bioinformatics) - 時間2021-05-06 (Thu.) 14:00 ~ 16:00
- 地點資訊所新館101演講廳
摘要
Due to different mutation profiles in patients, personalized medicine is the most desirable future for cancer therapy. However, a comprehensive combinatory effect of chemotherapy treatments is difficult to achieve due to limited tumor tissue obtained form biopsy. Microinjection and fabrication procedures were developed to assist for testing for effectiveness of combinatorial effect of chemotherapies using limited number of cells. We have tested the combinatorial effect of chemotherapies on our system to find out the best condition. The resulted were evaluated in different cancer cell lines and confirmed in xenograft tumor models. We are currently testing the effectiveness of our system using genetically modify cancer animal model.
BIO
Dr. Hsinyu Lee received his doctoral degree from UCSF. His research is focused on exploring the physiological functions of lysophospholipids, including LPA and S1P. From the efforts of his group, they have successfully demonstrated the roles of LPA1 and LPA3 receptors during lymphangiogenesis and hematopoiesis processes. Dr. Lee is also investigating the roles of lysophospholipids during tumorigenesis process in different cancer, including gastric cancer, prostate cancer and neuroblastoma. He is currently the Director for Professional Master Program for Biotechnology Major (PMBM) of National Taiwan University.